Moxogamma 0.3mg 30 tablets — Made in Germany — Free Delivery

Mild to moderate hypertension.

active ingredient: moxonidinum;

1 tablet contains moxonidine 0.2 mg or 0.3 mg or 0.4 mg

excipients: lactose, crospovidone, povidone K 25, magnesium stearate, Opadray B-1-7000 (contains hydroxypropyl methylcellulose, titanium dioxide (E 171), polyethylene glycol 400), red iron oxide (E 172).

Adults. Treatment should begin with a low dose of moxonidine - 0.2 mg per day. If the therapeutic effect is insufficient, after 3 weeks the dose can be increased to 0.4 mg. This dose can be taken as a single dose (morning) or divided into 2 doses (morning and evening). If within the next 3 weeks the results are unsatisfactory, the dose can be increased to a maximum of 0.6 mg, taken in 2 divided doses, morning and evening. A single dose of 0.4 mg of moxonidine and a maximum daily dose of 0.6 mg of moxonidine should not be exceeded. The dose of the preparation should be selected individually, depending on the patient's response.

The preparation can be taken regardless of food intake. The tablet should be taken with a sufficient amount of liquid.

Elderly patients. If there is no renal insufficiency, the dosage is the same as for adults.

Renal failure. For patients with moderate renal impairment (glomerular filtration rate> 30 ml / min, but < 60 ml / min), and for patients on hemodialysis, the initial dose should not exceed 0.2 mg, if necessary, the dose can be increased. In patients with severe renal impairment (glomerular filtration rate <30 ml/min), moxonidine is contraindicated.

Liver failure. There are no clinical data for patients with hepatic impairment. However, moxonidine is not metabolized in the liver, and a significant effect on its pharmacokinetics is not expected. Therefore, dosing for patients with mild to moderate hepatic impairment is the same as for adults. The preparation should not be interrupted suddenly, since the possibility of rebound hypertension as a "withdrawal effect" cannot be completely excluded. The preparation should be discontinued for 2 weeks, gradually reducing the dose.

Children. The efficacy and safety of the preparation in children have not been established, so the preparation should not be prescribed in this age group.